Literature DB >> 19129447

Modified vaccinia virus ankara triggers chemotaxis of monocytes and early respiratory immigration of leukocytes by induction of CCL2 expression.

Michael H Lehmann1, Wolfgang Kastenmuller, Judith D Kandemir, Florian Brandt, Yasemin Suezer, Gerd Sutter.   

Abstract

Orthopoxviruses commonly enter into humans and animals via the respiratory tract. Herein, we show that immigration of leukocytes into the lung is triggered via intranasal infection of mice with modified vaccinia virus Ankara (MVA) and not with the vaccinia virus (VACV) Elstree, Wyeth, or Western Reserve (WR) strain. Immigrating cells were identified as monocytes, neutrophils, and CD4(+) lymphocytes by flow cytometry and could be detected 24 h and 48 h postinfection. Using an in vitro chemotaxis assay, we confirmed that infection with MVA induces the expression of a soluble chemotactic factor for monocytes, identified as CCL2 (monocyte chemotactic protein-1 [MCP-1]). In contrast to infection with several other VACV strains, MVA induced the expression of CCL2, CCL3, CCL4, and CXCL10 in the human monocytic cell line THP-1 as well as in primary human monocytes. Thus, MVA, and not the VACV Elstree, Wyeth, or WR strain, consistently triggered the expression of a panel of chemokines, including CCL2, in the murine lung, correlating considerably with the immigration of leukocytes. Using CCL2-deficient mice, we demonstrate that CCL2 plays a key role in MVA-triggered respiratory immigration of leukocytes. Moreover, UV irradiation of MVA prevented CCL2 expression in vitro and in vivo as well as respiratory immigration of leukocytes, demonstrating the requirement for an activated molecular viral life cycle. We propose that MVA-triggered chemokine expression causes early immigration of leukocytes to the site of infection, a feature that is important for rapid immunization and its safety and efficiency as a viral vector.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19129447      PMCID: PMC2648269          DOI: 10.1128/JVI.01884-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  52 in total

Review 1.  Pulmonary defence mechanisms.

Authors:  L P Nicod
Journal:  Respiration       Date:  1999       Impact factor: 3.580

2.  Blockade of chemokine activity by a soluble chemokine binding protein from vaccinia virus.

Authors:  A Alcamí; J A Symons; P D Collins; T J Williams; G L Smith
Journal:  J Immunol       Date:  1998-01-15       Impact factor: 5.422

Review 3.  Chemokines.

Authors:  B J Rollins
Journal:  Blood       Date:  1997-08-01       Impact factor: 22.113

4.  Monocyte chemotactic proteins MCP-1, MCP-2, and MCP-3 are major attractants for human CD4+ and CD8+ T lymphocytes.

Authors:  P Loetscher; M Seitz; I Clark-Lewis; M Baggiolini; B Moser
Journal:  FASEB J       Date:  1994-10       Impact factor: 5.191

5.  Expression of foreign genes in cultured human primary macrophages using recombinant vaccinia virus vectors.

Authors:  C C Broder; P E Kennedy; F Michaels; E A Berger
Journal:  Gene       Date:  1994-05-16       Impact factor: 3.688

6.  NF-kappa B and Sp1 regulate transcription of the human monocyte chemoattractant protein-1 gene.

Authors:  A Ueda; K Okuda; S Ohno; A Shirai; T Igarashi; K Matsunaga; J Fukushima; S Kawamoto; Y Ishigatsubo; T Okubo
Journal:  J Immunol       Date:  1994-09-01       Impact factor: 5.422

7.  Monocyte chemoattractant protein 1 (MCP-1) gene expression in dilated cardiomyopathy.

Authors:  M H Lehmann; H Kühnert; S Müller; H H Sigusch
Journal:  Cytokine       Date:  1998-10       Impact factor: 3.861

8.  Abnormalities in monocyte recruitment and cytokine expression in monocyte chemoattractant protein 1-deficient mice.

Authors:  B Lu; B J Rutledge; L Gu; J Fiorillo; N W Lukacs; S L Kunkel; R North; C Gerard; B J Rollins
Journal:  J Exp Med       Date:  1998-02-16       Impact factor: 14.307

9.  Interleukin-2 regulates CC chemokine receptor expression and chemotactic responsiveness in T lymphocytes.

Authors:  P Loetscher; M Seitz; M Baggiolini; B Moser
Journal:  J Exp Med       Date:  1996-08-01       Impact factor: 14.307

10.  Eotaxin-2, a novel CC chemokine that is selective for the chemokine receptor CCR3, and acts like eotaxin on human eosinophil and basophil leukocytes.

Authors:  U Forssmann; M Uguccioni; P Loetscher; C A Dahinden; H Langen; M Thelen; M Baggiolini
Journal:  J Exp Med       Date:  1997-06-16       Impact factor: 14.307

View more
  41 in total

1.  Selective induction of host genes by MVA-B, a candidate vaccine against HIV/AIDS.

Authors:  Susana Guerra; José Manuel González; Núria Climent; Hugh Reyburn; Luis A López-Fernández; José L Nájera; Carmen E Gómez; Felipe García; José M Gatell; Teresa Gallart; Mariano Esteban
Journal:  J Virol       Date:  2010-06-09       Impact factor: 5.103

2.  In vivo imaging of inflammasome activation reveals a subcapsular macrophage burst response that mobilizes innate and adaptive immunity.

Authors:  Pervinder Sagoo; Zacarias Garcia; Beatrice Breart; Fabrice Lemaître; David Michonneau; Matthew L Albert; Yves Levy; Philippe Bousso
Journal:  Nat Med       Date:  2015-12-21       Impact factor: 53.440

3.  Production of prostaglandin E₂ in response to infection with modified vaccinia Ankara virus.

Authors:  Justin J Pollara; April H Spesock; David J Pickup; Scott M Laster; Ian T D Petty
Journal:  Virology       Date:  2012-04-23       Impact factor: 3.616

Review 4.  Viruses as vaccine vectors for infectious diseases and cancer.

Authors:  Simon J Draper; Jonathan L Heeney
Journal:  Nat Rev Microbiol       Date:  2010-01       Impact factor: 60.633

Review 5.  Vaccinia virus vaccines: past, present and future.

Authors:  Bertram L Jacobs; Jeffrey O Langland; Karen V Kibler; Karen L Denzler; Stacy D White; Susan A Holechek; Shukmei Wong; Trung Huynh; Carole R Baskin
Journal:  Antiviral Res       Date:  2009-06-26       Impact factor: 5.970

6.  Preclinical studies of a modified vaccinia virus Ankara-based HIV candidate vaccine: antigen presentation and antiviral effect.

Authors:  Samantha Brandler; Alice Lepelley; Marion Desdouits; Florence Guivel-Benhassine; Pierre-Emmanuel Ceccaldi; Yves Lévy; Olivier Schwartz; Arnaud Moris
Journal:  J Virol       Date:  2010-03-10       Impact factor: 5.103

7.  Chemokine binding protein vCCI attenuates vaccinia virus without affecting the cellular response elicited by immunization with a recombinant vaccinia vector carrying the HPV16 E7 gene.

Authors:  Pavel Gabriel; Katarina Babiarova; Kamila Zurkova; Jitka Krystofova; Petr Hainz; Luda Kutinova; Sarka Nemeckova
Journal:  Viral Immunol       Date:  2012-10       Impact factor: 2.257

8.  Immune requirements of post-exposure immunization with modified vaccinia Ankara of lethally infected mice.

Authors:  Henning Lauterbach; Ronny Kassub; Juliane Pätzold; Jana Körner; Michael Brückel; Admar Verschoor; Paul Chaplin; Mark Suter; Hubertus Hochrein
Journal:  PLoS One       Date:  2010-03-11       Impact factor: 3.240

9.  Harnessing the unique local immunostimulatory properties of modified vaccinia Ankara (MVA) virus to generate superior tumor-specific immune responses and antitumor activity in a diversified prime and boost vaccine regimen.

Authors:  James W Hodge; Jack Higgins; Jeffrey Schlom
Journal:  Vaccine       Date:  2009-05-29       Impact factor: 3.641

10.  Induced bronchus-associated lymphoid tissue serves as a general priming site for T cells and is maintained by dendritic cells.

Authors:  Stephan Halle; Hélène C Dujardin; Nadja Bakocevic; Henrike Fleige; Heike Danzer; Stefanie Willenzon; Yasemin Suezer; Günter Hämmerling; Natalio Garbi; Gerd Sutter; Tim Worbs; Reinhold Förster
Journal:  J Exp Med       Date:  2009-11-16       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.